Oren Gilad, President/CEO at Aprea Therapeutics, Inc. (APRE), bought 1,150 shares at $2.54 ($3K) on 2024-10-10, disclosed to the SEC on 2024-10-15.
Open-market purchase of $3k APRE by President/CEO. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.54 | 150 | $381 | 12.8% |
| 2 | $2.59 | 1,000 | $3K | 87.2% |
| Total | $2.58 avg | 1,150 | $3K | 100% |
| Filing → |
| APRE | BUY | 2024-10-24 | $2K | — | Filing → |
| APRE | BUY | 2024-10-16 | $725 | — | Filing → |
| APRE | BUY | 2024-03-14 | $15K | — | Filing → |